The current leading Zika vaccine candidates in clinical testing are based on live or killed virus 9 platforms, which have safety issues, especially in pregnant women. Zika subunit vaccines, 10 however, have shown poor performance in preclinical studies. We hypothesized that Zika 11
Introduction 27
Zika virus (ZIKV) is an enveloped single stranded RNA virus that is transmitted by mosquito 28 vectors. As a member of the flavivirus genus, ZIKV shares many structural features with other 29 medically important flaviviruses such as Wes Nile virus, yellow fever virus, and dengue virus 30 (DENV). The flavivirus envelope (E) protein is a major target of neutralizing and protective human 31
antibodies. E oligomers form complex quaternary structure epitopes on the viral surface which 32 are of particular importance as protective human antibodies bind to these higher order protein 33 structures 1 . 34 ZIKV infection during pregnancy can result in neurodevelopmental defects (congenital Zika 35 syndrome). This has stimulated work on subunit vaccines, as live attenuated and other replicating 36 virus vaccines are contraindicated during pregnancy. However, subunit vaccines based on 37 recombinant E proteins (rE) have performed poorly in preclinical studies compared to virus or 38 virus-like particle (VLP) vaccines 2-6 . In aqueous solution, flavivirus rE are in a dynamic equilibrium 39 that favors the monomer over the dimer at physiological temperature, which likely explains poor 40 binding by potently neutralizing human antibodies targeting quaternary epitopes and the overall 41 poor immunogenicity of rE antigens in pre-clinical studies 2,7,8 . 42 43 44 45
Results

46
Expression of ZIKV rE monomers and homodimers. 47
Here, to investigate if ZIKV rE dimers are better subunit vaccine antigens than monomers, we 48 expressed ZIKV rE variants (aa1-402) that are monomers (rE M ) or stable dimers (rE D ) under 49 physiological conditions. We generated stable ZIKV rE D proteins as previously described for 50 DENV E protein by introducing a disulfide bridge (A264C) in the E-domain II interactive region of 51 the homodimer 9,10 (Fig.1A) . The oligomeric state of the purified rE M and rE D proteins were 52 confirmed by protein gel electrophoresis (Fig.1B) . The stable rE D , but not the rE M , was efficiently 53 recognized by neutralizing mAbs that have dimer-dependent quaternary footprints, such as ZIKV 54 specific mAbs A9E, G9E, and ZKA-230 and flavivirus cross-reactive mAbs C8 and C10 (Fig 1C) . 
64
ZIKV rE D , but not rE M , induces neutralizing antibodies. 66
After confirming that rE D was a dimer displaying native quaternary epitopes, we immunized 67 C57BL/6 mice with 5 µg rE M , 5 µg rE D , 5 µg rE M +alum, or 5 µg rE D +alum and analyzed ZIKV 68 specific IgG and neutralizing antibody titers over time ( Fig.2A ). In the absence of alum, rE M and 69 rE D induced minimal IgG titers after the initial immunization, but this response increased upon 70 boosting ( Fig.2B and C) . In the alum adjuvanted groups, high IgG titers were observed even after 71 the prime alone, with minimal change upon boosting ( Fig.2B ). Although rE M elicited ZIKV-binding 72 antibodies in the absence of alumn, these antibodies failed to neutralize ZIKV (Fig. 2D) . In 73 contrast, non-adjuvanted rE D elicited ZIKV-neutralizing antibodies (Fig.2D ). The addition of alum 74 adjuvant elevated neutralizing antibody levels in both groups, but neutralizing titers were 75 significantly higher after rE D immunization compared to rE M . Our results demonstrate that, while 76 both antigens stimulated ZIKV-specific IgG, the rE D stimulated antibodies that are more potently 77 neutralizing compared to the rE M stimulated antibodies. 
ZIKV rE D stimulates antibodies that target complex epitopes on the virus particle. 89
We next performed experiments to determine if antibodies stimulated by rE M and rE D antigens 90 recognized different epitopes on the ZIKV E protein. Many flavivirus type-specific antibodies 91 recognize relatively simple epitopes on domain III of the E protein (EDIII), whereas other type-92 specific antibodies recognize more complex quaternary structure epitopes displayed on E protein 93 homodimers or higher order structures that cover the viral surface. Most EDIII-specific neutralizing 94 antibodies have been isolated from mice immunized with inactivated flavivirus antigens 11-13 . In 95 contrast, most quaternary epitope directed neutralizing antibodies have been isolated from people 96 infected with wild type flaviviruses 7,14-17 . In fact, recent studies demonstrate that neutralizing 97 antibodies in people exposed to flavivirus infections or effective live attenuated vaccines 98 predominantly recognize quaternary epitopes, with simple EDIII epitopes accounting for only a 99 minor fraction of neutralizing antibodies 18-22 . To compare levels of EDIII directed antibodies in 100 animals immunized with rE M or rE D , we used recombinant ZIKV-EDIII conjugated to magnetic 101 beads to deplete mouse immune sera of EDIII binding antibodies (Fig.3A ). We tested control 102 depleted and EDIII antibody depleted immune sera to estimate the levels of binding ( Fig.3B ) and 103 neutralizing antibodies ( Fig.3C ) in each sample targeting epitopes on EDIII. In mice immunized 104 with rE M , ~70% (rE M group) and ~60% (rE M +alum group) of total ZIKV-specific IgG recognized 105 epitopes on EDIII ( Fig.3B ). On the other hand, significantly less EDIII-specific antibodies were 106 induced after immunization with rE D (~30% for rE D and ~20% for rE D +alum). The antibody binding patterns were also reflected in the ZIKV neutralization assays. The majority of neutralizing 108 antibodies in the rE M +alum group were lost following depletion with EDIII antigen (Fig.3C ). In 109 contrast, no loss of neutralization was observed in the animals immunized with rE D or rE D + alum 110 after the removal of EDIII-binding antibodies (Fig.3C ). We conclude that the rE M antigen induces 111 an EDIII focused antibody response that is poorly neutralizing, whereas rE D antigens stimulate 112 robust neutralizing antibody responses that target epitopes distinct from simple EDIII epitopes. 113
We recently isolated two ZIKV-specific strongly neutralizing human mAbs (A9E and G9E) from a 114 person who was infected with ZIKV in 2016 23 . These antibodies map to complex epitopes on 115 domain I (A9E) and domain II (G9E) of ZIKV E protein 23 . Moreover, antibody blockade assays 116 using these mAbs and human immune sera indicated that the epitopes targeted by these mAbs 117 also are targeted by antibodies in immune serum from Zika patients but not dengue patients 23 . 118
We used a blockade of binding (BOB) assay to test if mice immunized with rE M or rE D developed 119 antibodies that recognize A9E or G9E epitopes on ZIKV. We also tested if rE M or rE D antigens 120 stimulated antibodies that targeted the epitope of human mAb EDE C10 17 which binds to a E 121 dimer dependent epitope that is conserved between DENV and ZIKV. Sera from mice immunized 122 with rE M did not block binding of A9E, G9E, and C10 mAbs to ZIKV (Fig.3D ). In contrast, sera 123 from mice immunized with rE D antigen efficiently blocked binding of A9E and G9E (~80%) and 124 partially blocked binding of EDEC10 (~35%) to ZIKV. These results demonstrate that the rE D 125 antigen and natural ZIKV infections stimulate antibodies that target similar complex epitopes on 126 the virion. The rE M fails to induce similar antibodies and directs the antibody response to simple 127 epitopes on ZIKV EDIII. 128
129
ZIKV rE D induces protective antibodies in mice. 144
Next, we investigated if the immune sera of mice vaccinated with rE M +alum and rE D +alum could 145 protect mice from lethal ZIKV challenge. We immunized wild-type mice as previously described 146 (Fig.2) , and transferred heat-inactivated immune sera to Ifnar1 -/mice which are highly 147 susceptible to ZIKV. Ifnar1 -/mice were challenged with 1000 FFU of ZIKV H/PF/2013, 1 day post 148 serum transfer. Mice were monitored for weight loss and ZIKV induced disease, and mice were 149 bled at day 0 (before virus challenge), day 4 and day 14 (Fig.4A ). The potently neutralizing mAb 150 G9E was used as a positive control for protection against ZIKV infection 23 . Mice that received 151 G9E or serum from rE D +alum immunization were completely protected against weight loss and 152 disease signs. In contrast, mice receiving rE M +alum serum exhibited significant weight loss and 153 hindlimb paralysis ( Fig.4B) . At 4 days post challenge, viremia levels in the rE D +alum group were 154 significantly reduced compared to the rE M +alum and vehicle groups (Fig.4C ). We also measured 155 ZIKV specific IgG titers ( Fig.4D ) and neutralizing antibody titers (Fig.4E) at days 0 and 14. Mice 156 receiving rE M +alum and rE D +alum immune sera showed similar ZIKV-specific IgG titers at day 0, 157 which were marginally higher for both groups at day 14. On the other hand, neutralizing antibody 158 titers were much higher at day 14 for both groups, likely caused by an endogenous immune 159 response elicited against replicating virus in the challenged mice ( Fig. 4C) . 160 Neutralizing antibody titers were determined as previously described 28 . In short, Vero-81 cells 274 were seeded (25000 cells/well) and incubated at 37°C overnight. Immunized mice sera was 275 serially diluted in OptiMEM (Gibco) supplemented with 2% FBS and incubated for 45 minutes at 276 37°C with the amount of ZIKV previously determined to infect ~15% of the cells. Cells were 277 subsequently washed with OptiMEM and overlaid with the diluted sera/virus mix for 2 hours at 278 medium at 37°C. The next day, cells were washed with PBS and detached from the plate by 280 trypsin (Gibco). Cells were subsequently fixed in 4% paraformaldehyde and washed in 281 permeabilization buffer and blocked with 1% normal mouse serum in perm buffer for 30 minutes 282 at room temperature. Following incubation, infected cells were detected by staining with Alexa-283 488 conjugated 1M7 mAb for 1 hour at 37°C. Next, cells were washed in perm buffer and 284 resuspended in 200 µl FACS buffer. The percentage of infected cells were determined using the 285 Guava Flow Cytometer (EMD Millipore) and the neutralizing capacity was expressed as neut 50 286 (the dilution where 50% of the virus is neutralized), calculated by GraphPad Prism software. 287 288
Depletion of EDIII-binding IgG from mouse serum. 289
Bacterially expressed ZIKV EDIII proteins (C-terminal 6 × His-tag) were conjugated to Ni-NTA 290
Magnetic beads (Thermo Scientific) following manufacturers protocol. In short, 1 mg of Ni-NTA 291 beads were washed in equilibration buffer and incubated on a rotator with 60 µg of ZIKV-EDIII or 292 MBP-His (control depletions) for 1 hour at 37°C. Next, the beads were washed in equilibration 293 buffer and divided in 2 tubes for two rounds of depletions. Mouse immune serum was diluted 1:20 294 in PBS and incubated with magnetic beads for 1 hour at 37°C on a rotator. Following incubation, 295 the depleted serum was separated from the beads and stored at 4°C for subsequent IgG ELISA 296 and neutralization assays. The percentage of ZIKV EDIII binding antibodies was calculated by 297 dividing the EDIII-depleted IgG titers by the control-depleted IgG titers. The percentage of ZIKV 298 EDIII neutralizing antibodies was calculated by dividing the EDIII depleted neut 50 by the control 299 depleted neut 50 . 300
301
C10 blockade of binding (BOB) assay. 302
High-binding ELISA plates were coated with 2 ng/µl 1M7 human mAb in PBS for 1 hour at 37°C. 303
Next, plates were blocked with 3% skim milk in PBS+0.05% Tween for 30 minutes at 37°C. After 304 blocking, plates were washed in PBS+0.2% Tween and incubated with ZIKV H/PF/2013 for 1 hour at 37°C. The plates were washed and incubated with serially diluted immunized mouse sera for 306 1 hour at 37°C. Next, the plates were washed and incubated with alkaline phosphatase (AP)-307 conjugated A9E, G9E or C10 human mAb at 2 ng/µl for 1 hour at 37°C. Following incubation, the 308 plates were washed and developed with AP-substrate and absorbance was measured at 405nm. Nuclease free H 2 O). Next, samples were analyzed in a Bio-Rad CFX96 Thermocycler according 318 to the following program: 10 mins at 50°C, 2 mins at 95°C, (10 sec at 95°C, 20 sec at 60°C) × 40 319 cycles. RNA was isolated from a known quantity of ZIKV H/PF/2013 to generate a standard curve. 320 321
